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Abstract
Background: Biphasic immediate-release (IR)/extended-release (ER) hydrocodone bitartrate (HB)/acetaminophen
(APAP) 7.5/325-mg tablets are formulated with gastroretentive ER drug delivery technology that has been
associated with clinically meaningful food effects in other approved products. Two phase 1 studies evaluated
potential effects of food on single-dose pharmacokinetics of IR/ER HB/APAP tablets.
Methods: These were single-center, open-label, randomized, single-dose, 3-period crossover studies in healthy
volunteers (aged 18–55 years). IR/ER HB/APAP was administered as a single 2-tablet dose (study 1) or 3-tablet dose
(study 2) under fed (high- and low-fat) and fasted conditions. Area under the plasma concentration-time curve
from 0 h to time t (AUC0–t) and from time 0 extrapolated to infinity (AUC0–inf) and maximum observed plasma
concentration (Cmax) of hydrocodone and APAP under fed versus fasted conditions were compared using analysis
of variance. A 90 % confidence interval of the geometric least squares mean ratio fully contained within 80 to
125 % indicated no treatment difference. Safety and tolerability were assessed.
Results: Forty of 48 participants in study 1 and 21 of 30 in study 2 completed all treatments. In both studies, under
fed (high- or low-fat meal) versus fasted conditions, 90 % CIs for AUC0–t and AUC0–inf for both hydrocodone and
APAP were entirely contained within the bioequivalent range (80–125 %), indicating that high- and low-fat meals
did not affect the extent of exposure. In both studies, a high-fat meal did not affect the Cmax for hydrocodone.
Hydrocodone Cmax was not affected by a low-fat meal in study 1 but increased by approximately 19 % in study 2.
A high-fat meal decreased APAP Cmax by approximately 20 % (study 1) and 13 % (study 2); a low-fat meal
decreased APAP Cmax by 22 % (study 1) and 21 % (study 2). Approximately 50 % of participants in both studies
reported ≥1 treatment-emergent adverse event (TEAE), with no notable difference based on food intake. There
were no serious or severe AEs. The most common TEAEs were nausea, vomiting, and dizziness.
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Conclusions: Pharmacokinetic and safety findings were similar regardless of food intake. TEAEs were consistent
with those reported with low-dose combination opioids. IR/ER HB/APAP can be administered without regard
to food.
Trial registration: ClinicalTrials.gov NCT02561650 and NCT02561741.
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Background
Typically, acute pain is treated with immediate-release
(IR) opioid formulations to facilitate rapid onset of anal-
gesia, whereas extended-release (ER) formulations are pre-
ferred for chronic pain because they provide long-lasting
analgesia with less-frequent dosing [1]. Additional poten-
tial advantages of ER opioids include fewer concentration
peaks and troughs throughout the day, which may im-
prove pain control and compliance, as well as prevent
sleep disruption as a result of less-frequent dosing [2, 3].
Fixed-dose combination (FDC) opioid analgesics may pro-
vide additive analgesic efficacy while allowing a reduction
in the total dose of each component; this may reduce the
risk of dose-related adverse events (AEs) associated with
either component administered as monotherapy [4, 5].
However, until recently, no opioid FDC with ER properties
has been available.
The most frequently prescribed drug (of any kind) in
the United States is the FDC analgesic IR hydrocodone
bitartrate (HB)/acetaminophen (APAP) [6]. Biphasic IR/
ER HB/APAP 7.5/325-mg tablets (MNK-155; Mallinckrodt
Pharmaceuticals, Hazelwood, MO) are in development for
the treatment of moderate to severe acute pain for which
nonopioid analgesics are inadequate. IR/ER HB/APAP de-
livers 25 % of its HB and 50 % of the APAP from an IR
layer for rapid onset of analgesia and employs a gastrore-
tentive matrix (Acuform®, Depomed, Inc., Newark, CA) to
allow sustained release of the remainder of the HB (75 %)
and APAP (50 %) over a 12-h dosing period. A
similarly formulated IR/ER oxycodone/APAP tablet
(XARTEMIS™ XR; formerly MNK-795, Mallinckrodt
Brand Pharmaceuticals, Inc., Hazelwood, MO) was ap-
proved for the management of acute pain severe enough
to require opioid treatment and for which alternative
treatment options are inadequate [7].
Given that IR/ER HB/APAP is formulated to provide
both a rapid and an extended duration of action, it is ne-
cessary to characterize the extent and rate of exposure
of hydrocodone and APAP during treatment with IR/ER
HB/APAP in patients treated under different conditions.
In two phase 1 trials, single- and steady-state ad-
ministration of IR/ER HB/APAP under fasted conditions
was found to provide total and peak exposure similar to
IR HB/APAP with less-frequent dosing (Data on file,
Mallinckrodt, Hazelwood, MO). Potential effects of food
on absorption of IR/ER HB/APAP have yet to be
characterized.
Clinically relevant food effects have been observed with
ER gabapentin tablets (Gralise®, Depomed, Inc., Newark,
CA) [8] and ER metformin HCl tablets (Glumetza®,
Santarus, Inc., San Diego, CA) [9] formulated using the
same gastroretentive matrix used for IR/ER HB/APAP and
IR/ER OC/APAP, with high fat content (>50 % calories
from fat) augmenting these effects. For ER gabapentin,
compared with the fasted state, low-fat and high-fat meals
increased the extent of absorption as measured by max-
imum observed plasma concentration (Cmax) by 33 to 84 %,
respectively, and area under the plasma concentration-
time curve (AUC) by 33 to 118 %, respectively [8]. For ER
metformin HCl, compared with the fasted state, low-fat
and high-fat meals increased AUC by 38 and 73 %, re-
spectively, but Cmax was unaffected. However, for IR/ER
OC/APAP, food and fat content do not alter the extent or
rate of absorption of oxycodone or APAP compared with
the fasted state [10].
It is important to ascertain whether food and fat con-
tent of a meal might affect the rate and extent of absorp-
tion of the active pharmaceutical ingredients of IR/ER
HB/APAP relative to the fasted state, as observed with
some products using the same ER matrix. To that end,
two phase 1 studies in healthy adult volunteers evaluated
the effect of fed (high- and low-fat meals) versus fasted
conditions on single-dose pharmacokinetics and bioavail-
ability following administration of IR/ER HB/APAP 7.5/
325-mg tablets given as a single 2-tablet dose (study 1) or
a single 3-tablet dose (study 2).
Methods
Study design
Two phase 1, single-center (PPD Phase I Clinic, Austin,
TX, USA), open-label, randomized, single-dose, 3-period
crossover trials were conducted. In both studies, partici-
pants underwent screening evaluations to determine eli-
gibility within 30 days of period 1 check-in. During the
treatment period, participants were randomly assigned
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to 1 of 6 sequences of 3 treatments, each separated by a
6-day washout interval.
Each study received institutional review board approval
(IntegReview Ethical Review Board, Austin, TX, USA) and
was conducted in accordance with the Good Clinical
Practice Guidelines of the International Conference on
Harmonisation. All participants provided written in-
formed consent. The two trials that were registered with




Participants were men or nonpregnant, nonlactating
women aged 18 to 55 years with health status considered
by investigators as “healthy normal” at screening and
check-in assessments. Participants had a body mass
index 19 to 30 kg/m2 with a minimum weight of 110 lb
(women) or 130 lb (men).
Exclusion criteria
Exclusion criteria included an acute illness within 14 days
before period 1 check-in; electrocardiogram abnormal-
ities; laboratory results falling outside of the upper or
lower limits of normal; history of significant psychiatric
illness requiring hospitalization, psychotherapy, and/or
medication within the previous 3 years. Participants
were also excluded if they had a history of any condition
that might interfere with the absorption, distribution,
metabolism, or excretion of the study drug.
Participants were excluded from the study if, during
any study period, they experienced emesis any time after
dosing at hour 0 through the 48-h postdose blood col-
lection. This was to ensure that participants had ad-
equate drug exposure to allow accurate assessment of
pharmacokinetic parameters. Additional exclusion cri-
teria included positive urine test results for drugs of
abuse or alcohol; history of or treatment for substance
abuse, narcotic addiction; use of nicotine-containing
products within 6 months before period 1 check-in; and
use of prescription drugs or nonprescription drugs, vita-
mins, minerals, or dietary/herbal supplements within
14 days before period 1 check-in and for the duration of
the study. Finally, participants were excluded if they had
undergone abdominal and/or pelvic surgery, including
cholecystectomy, gastric bypass, or gastric band surgery,
and cardiothoracic surgery.
Study treatments
IR/ER HB/APAP 7.5/325-mg tablets were given as a
single 2-tablet dose (study 1) or a single 3-tablet dose
(study 2) under fasted (reference) and fed (test) condi-
tions. For their predose meals, participants received a
US Food and Drug Administration–standardized high-
fat meal with approximately 50 % of 1000 ± 100 cal com-
ing from fat [treatment A], a low-fat meal with 25 to
30 % of 800 ± 80 cal coming from fat [treatment B]
meal), or fasted (treatment C). To successfully complete
the study, participants were required to complete all 3
periods (completers).
Assessments
Blood samples and pharmacokinetics
AUC from 0 h to time t (AUC0–t) and from time 0 ex-
trapolated to infinity (AUC0–inf ) and Cmax of hydroco-
done and APAP were compared across the 3 treatments
(high-fat meal, low-fat meal, and fasting). Time to Cmax
(tmax), time to first measurable concentration (tlag), ap-
parent first-order terminal elimination rate constant
(Kel), and apparent plasma terminal elimination half-life
(t1/2) were also assessed.
For determination of hydrocodone and APAP concen-
trations, whole blood samples (6 mL) were collected via
venipuncture from each participant in prechilled
lavender-top vacuum blood collection tubes containing
K2EDTA anticoagulant. Blood was collected at predose
(up to 60 min before dosing); after dosing at 15, 30, and
45 min: and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 18,
20, 24, 36, and 48 h. Blood samples were placed in an
ice bath/cryoblock immediately after collection and cen-
trifuged at approximately 4 °C. Within 1 h of collection,
the plasma fraction was withdrawn by pipette, divided
equally into 2 aliquots in labeled polypropylene screw-
cap tubes, and frozen to ≤ −70 °C (study 1) or ≤ −20 °C
(study 2). Samples were shipped from the PPD Phase I
Clinic and remained frozen until received for assay at
the PPD Bioanalytical Lab (Middleton, WI). A summary
of the bioanalytical method is listed in an additional file
(see Additional file 1). Hydrocodone and APAP concen-
trations were measured using a high-performance liquid
chromatography/tandem mass spectrometry assay that
was validated over a calibration range of 0.100 to
50.0 ng/mL for HC and a range of 100 to 50,000 ng/mL
(study 1) or 15,000 ng/mL (study 2) for APAP. HC-d6
and APAP-d4 were used as the internal standards. Study
data were collected using the Analyst Version 1.4.2
(Applied Biosystems, Carlsbad, CA) and PPD Assist
LIMS Version 5 (PPD, Richmond, VA). The assay method
was validated for linearity, precision, accuracy, ruggedness,
recovery, and specificity. Studies to confirm both short-
term stability and long-term storage stability were per-
formed. Analyses of samples were performed following
the principles of Good Laboratory Practice and PPD’s
standard operating procedures.
Safety and tolerability
Treatment-emergent adverse events (TEAEs), serious
adverse events (SAEs), vital signs, and pulse oximetry
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were assessed at baseline and throughout the 48 h after
dosing. TEAEs, treatment-related TEAEs, severity of
TEAEs, and TEAEs leading to early discontinuation
were summarized by system organ class and were coded
using the Medical Dictionary for Regulatory Activities,
version 14.0. Physical examinations were performed at
screening, check-in to each study period, and at study
exit or early termination. A 12-lead electrocardiogram
and laboratory tests (chemistry, hematology, and urinaly-
sis) were performed at screening and final visit or early
termination.
Statistical methods
Blood samples and pharmacokinetics
Individual plasma concentration versus time data were
used to estimate the pharmacokinetic parameters of
hydrocodone and APAP by standard noncompartmental
methods. Pharmacokinetic parameters were summarized
by treatment using descriptive conditions. Geometric
means were included for AUC0–t, AUC0–inf, and Cmax.
To analyze the effect of food, an analysis of variance
using the SAS/STAT® version 9.1.3 (SAS Institute, Cary,
NC) general linear mixed model procedure was con-
ducted with the natural log-transformed pharmacoki-
netic parameters (AUC0–t, AUC0–inf, and Cmax) as the
dependent variables, with sequence, treatment, and
period as fixed effects and participants nested within se-
quence as a random effect. Treatment A (fed condition,
high-fat meal) was compared to Treatment C (fasted
condition), Treatment B (test: fed condition, low-fat
meal) was compared to Treatment C (reference: fasted
condition), and Treatment A (test: fed condition, high-
fat meal) was compared to Treatment B (reference: fed
condition, low-fat meal). A 90 % confidence interval (CI)
of the geometric least squares mean (LS mean) ratio
fully contained within 80.00 to 125.00 % for AUC0–t,
AUC0–inf, and Cmax indicated no difference between
each treatment.
The Wilcoxon signed-rank test was performed to
evaluate differences in tmax and tlag, with a P value ≤0.05
indicating a significant difference between treatments.
Safety and tolerability
Safety was assessed in all participants who received ≥1
dose of study drug (all dosed participants). All TEAEs
were summarized using descriptive statistics.
Results
Participant disposition and characteristics
A total of 48 participants were enrolled in study 1, and
30 were enrolled in study 2; 40 participants completed
study 1, and 21 completed study 2. Of the 78 partici-
pants in total, 15 discontinued because of AEs, of which
14 discontinued because of the TEAE of vomiting, as
required by the protocol. Twelve of the 14 participants
who vomited were women.
Demographics and baseline characteristics of all dosed
participants and completers of both studies are summa-
rized in Table 1. Mean age, height, weight, and body mass
index were generally similar between all dosed participants
in study 1 and study 2. All participants in study 1 were ei-
ther white or black; study 2 enrolled 1 participant each of
Asian and American Indian/Alaskan Native descent.
Pharmacokinetics
Hydrocodone
In both studies, plasma hydrocodone concentrations
rose rapidly following administration of a single 2-tablet
or 3-tablet dose of IR/ER HB/APAP, exhibiting a single
peak concentration early in treatment with no trough
between the IR and ER phases (Fig. 1). With the 2-tablet
dose, plasma concentration peaked at 6 h after a high-fat
meal and 4 h after a low-fat meal or under fasted condi-
tions. Peak plasma concentrations with the 3-tablet dose
were reached after 4 h under fasted conditions and both
fed conditions.
After a single dose of IR/ER HB/APAP, mean total
(AUC) exposure and peak (Cmax) exposure to hydroco-
done were slightly higher after low-fat and high-fat meals
compared with fasted conditions with both the 2-tablet
(study 1) and 3-tablet (study 2) doses, but the differences
were not clinically meaningful (Table 2). Median tmax of
hydrocodone was unchanged compared with fasted condi-
tions after a low-fat meal and delayed 2 h after a high-fat
meal after the 2-tablet dose compared with the fasted con-
dition. Median tmax was delayed by 1 h after the low-fat
and high-fat meals after the 3-tablet dose. Median absorp-
tion lag time (tlag) of hydrocodone increased by 0.25 h
when IR/ER HB/APAP was administered after a low-fat
meal compared with fasted conditions in both studies.
After a single 2- or 3-tablet dose of IR/ER HB/APAP,
90 % CIs for AUC0–t and AUC0–inf for hydrocodone were
entirely contained within the bioequivalent range (80–
125 % of fasted-state value), indicating that the high-fat and
low-fat meals did not affect the extent of exposure. After
the 2-tablet dose, 90 % CI for Cmax for hydrocodone was
entirely contained within the bioequivalent range when ad-
ministered with a high-fat or low-fat meal (Table 3). After
the 3-tablet dose, 90 % CIs for Cmax for hydrocodone were
within the bioequivalent range when administered with a
high-fat meal but were partially outside the bioequivalent
range (110.9–128.3 %) when administered with a low-fat
meal, indicating that a low-fat meal increased peak expos-
ure by approximately 19 % compared with the fasted state.
Acetaminophen
Plasma APAP concentrations rapidly increased following
administration of a single 2-tablet or 3-tablet dose of IR/
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ER HB/APAP (Fig. 2). With the 2-tablet dose, Cmax was
attained after 2 h with the high-fat and low-fat meals
and <1 h under fasted conditions (Table 2). After 3 tab-
lets, plasma concentrations peaked in 1 h after a high-fat
meal, 3 h after a low-fat meal, and in <1 h under fasted
conditions.
After 2-tablet and 3-tablet doses, AUC values for
APAP were similar under fed and fasted conditions
(Table 2). However, with both doses, Cmax values for
APAP were decreased after low-fat and high-fat meals
compared with fasted conditions. After a 2-tablet dose,
median tmax of APAP was delayed by 1.25 h after low-fat
and high-fat meals compared with fasted conditions.
After the 3-tablet dose, median tmax of APAP was de-
layed by 2.25 h after a low-fat meal but only 0.25 h after
a high-fat meal. Median tlag of APAP appeared to be
slightly delayed under the low-fat fed condition after the
2-tablet dose but was unaffected after the 3-tablet dose.
In both studies, 90 % CIs for AUC0–t and AUC0–inf for
APAP were within the bioequivalent range, indicating
that the high- and low-fat meals did not affect the extent
of overall exposure (Table 3). After 2-tablet and 3-tablet
dosing, 90 % CIs for Cmax for APAP were partially out-
side the bioequivalent range compared with the fasted
condition, indicating that a high-fat or low-fat meal de-
creased peak exposure by approximately 20 % with the
Table 1 Demographics and baseline characteristics of all dosed participants and completers in studies 1 and 2
Characteristics Study 1 (2 tablets IR/ER HB/APAP) Study 2 (3 tablets IR/ER HB/APAP)
All dosed participants Completers All dosed participants Completers
(N = 48) (n = 40) (N = 30) (n = 21)
Mean (SD) age, y 33.3 (10.1) 33.2 (10.3) 35.2 (10.8) 36.1 (10.4)
Women, n (%) 24 (50.0) 18 (45.0) 15 (50.0) 7 (33.3)
Race, n (%)
White 36 (75.0) 31 (77.5) 25 (83.3) 18 (85.7)
Black 12 (25.0) 9 (22.5) 3 (10.0) 1 (4.8)
Asian 0 0 1 (3.3) 1 (4.8)
American Indian or Alaskan Native 0 0 1 (3.3) 1 (4.8)
Ethnicity, n (%)
Hispanic or Latino 17 (35.4) 15 (37.5) 11 (36.7) 7 (33.3)
Not Hispanic or Latino 31 (64.6) 25 (62.5) 19 (63.3) 14 (66.7)
Mean (SD) height, cm 167.9 (9.3) 168.6 (8.8) 168.7 (9.5) 171.1 (9.7)
Mean (SD) weight, kg 72.6 (12.3) 73.6 (12.6) 74.3 (11.0) 76.7 (11.5)
Mean (SD) body mass index, kg/m2 25.6 (3.0) 25.8 (3.1) 26.1 (2.8) 26.1 (2.5)
APAP = acetaminophen; ER = extended release; HB = hydrocodone bitartrate; IR = immediate release
Fig. 1 Mean plasma concentration of hydrocodone in (a) study 1 and (b) study 2
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Table 2 Pharmacokinetic estimates under fed and fasted conditions in study completers of studies 1 and 2
Drug/Parameter,
geometric mean (SD)
Study 1 (2 tablets IR/ER HB/APAP; n = 40a) Study 2 (3 tablets IR/ER HB/APAP; n = 21b)
High-fat meal Low-fat meal Fasted High-fat meal Low-fat meal Fasted
Hydrocodone
AUC0–t, ng•h/mL 301.50 (52.81) 299.72 (57.01) 280.10 (58.80) 392.61 (98.89) 401.63 (99.51) 361.21 (83.32)
AUC0–inf, ng•h/mL 303.66 (53.13) 301.95 (57.83) 282.94 (59.86) 395.03 (99.82) 404.25 (100.35) 365.70 (85.51)
Cmax, ng/mL 21.66 (4.88) 23.09 (3.79) 20.33 (4.33) 28.04 (6.29) 29.58 (6.69) 25.42 (6.15)
tmax, h
c 6.00 (2.00–11.00) 4.00 (2.00–7.00) 4.00 (2.00–7.00) 4.00 (1.00–12.00) 4.00 (2.00–12.00) 3.00 (1.00–5.00)
tlag, h
c 0.00 (0.00–1.07) 0.25 (0.00–0.75) 0.00 (0.00–0.50) 0.00 (0.00–0.75) 0.25 (0.00–0.50) 0.00 (0.00–0.25)
t½, h 5.58 (0.85) 5.85 (1.00) 6.43 (1.11) 5.25 (0.85) 5.54 (0.78) 6.35 (1.52)
APAP
AUC0–t, ng•h/mL 33,210.39 (10,402.75) 32,415.11 (9586.52) 32,149.34 (9431.97) 46,656.25 (12,228.35) 47,730.72 (12,238.72) 47,702.26 (13,034.74)
AUC0–inf, ng•h/mL 34,689.91 (10,672.37) 34,092.21 (9949.21) 34,803.59 (9635.34) 48,227.95 (12,104.97) 50,010.40 (12,223.51) 51,623.79 (11,493.91)
Cmax, ng/mL 4317.00 (1185.08) 4122.25 (877.19) 5307.00 (1419.43) 6250.95 (1646.83) 5733.33 (1389.04) 7740.48 (2488.56)
tmax, h
c 2.00 (0.25–6.05) 2.00 (0.75–7.00) 0.75 (0.25–5.00) 1.00 (0.50–3.00) 3.00 (0.50–8.00) 0.75 (0.50–2.00)
tlag, h
c 0.00 (0.00–0.63) 0.25 (0.00–0.50) 0.00 (0.00–0.25) 0.00 (0.00–0.25) 0.00 (0.00–0.50) 0.00 (0.00–0.25)
t½, h 5.37 (2.02) 5.68 (1.68) 7.37 (2.77) 5.80 (1.72) 7.07 (2.53) 8.13 (1.90)
APAP = acetaminophen; AUC0–inf = area under the plasma concentration-time curve from time 0 extrapolated to infinity; AUC0–t = area under the plasma concentration-time curve from 0 h to time t; Cmax = maximum
observed plasma concentration; ER = extended release; HB = hydrocodone bitartrate; IR = immediate release; t½ = apparent plasma terminal elimination half-life; tlag = time to first measurable concentration; tmax = time
to achieve Cmax
aWith the exception of APAP fasted AUC0–inf (n = 38) and APAP fasted t½ (n = 39)
















Table 3 Geometric LS mean ratios in study completers in studies 1 and 2
Drug/Parameter,
% (90 % CI)
Study 1 (2 tablets IR/ER HB/APAP; n = 40a) Study 2 (3 tablets IR/ER HB/APAP; n = 21b)
High-fat meal/Fasted Low-fat meal/Fasted High-fat meal/Low-fat meal High-fat meal/Fasted Low-fat meal/Fasted High-fat meal/Low-fat meal
Hydrocodone
AUC0–t, ng•h/mL 108.40 (104.44–112.51) 107.45 (103.53–111.52) 100.89 (97.22–104.69) 109.32 (105.53–113.25) 111.63 (107.83–115.55) 97.93 (94.67–101.32)
AUC0–inf, ng•h/mL 108.11 (104.14–112.24) 107.17 (103.23–111.26) 100.88 (97.19–104.72) 108.64 (104.87–112.54) 111.01 (107.24–114.92) 97.86 (94.60–101.24)
Cmax, ng/mL 106.66 (100.54–113.15) 114.75 (108.16–121.73) 92.95 (87.64–98.59) 114.71 (106.45–123.60) 119.27 (110.86–128.33) 96.17 (89.50–103.33)
APAP
AUC0–t, ng•h/mL 102.70 (100.05–105.42) 100.74 (98.15–103.41) 101.94 (99.32–104.63) 101.19 (95.65–107.05) 102.36 (96.87–108.16) 98.86 (93.65–104.36)
AUC0–inf, ng•h/mL) 100.32 (97.71–103.01) 98.66 (96.09–101.30) 101.69 (99.04–104.40) 98.30 (92.92–103.99) 101.64 (96.22–107.36) 96.72 (91.71–102.00)
Cmax, ng/mL 80.49 (75.44–85.88) 78.10 (73.20–83.33) 103.06 (96.62–109.93) 86.86 (77.33–97.55) 78.68 (70.23–88.16) 110.39 (98.72–123.43)
APAP = acetaminophen; AUC0–inf = area under the plasma concentration-time curve from time 0 extrapolated to infinity; AUC0–t = area under the plasma concentration-time curve from 0 h to time t; Cmax = maximum
observed plasma concentration; ER = extended release; HB = hydrocodone bitartrate; IR = immediate release; LS = least squares
aWith the exception of APAP fasted AUC0–inf (n = 38)















2-tablet dose and by 13 and 21 %, respectively, after the
3-tablet dose compared with the fasted condition.
Safety
Twenty-six (54.2 %) and 15 (50.0 %) participants re-
ported ≥1 TEAE after receiving the 2-tablet (study 1)
and 3-tablet (study 2) doses, respectively (Table 4). Al-
though statistical comparisons were not performed, there
were no notable differences in the overall incidence of
TEAEs after receiving IR/ER HB/APAP under fasted con-
ditions versus with a high-fat or low-fat meal. Individual
TEAEs and treatment-related AEs occurred with similar
frequencies between the 2-tablet and 3-tablet doses.
However, discontinuations due to AEs were more fre-
quent with the 3-tablet dose (n = 8, 26.7 %) than with
the 2-tablet dose (n = 7, 14.6 %). This difference was due
primarily to a greater frequency of nausea and vomiting
with the 3-tablet dose. Vomiting led to study discontinu-
ation in 6 (12.5 %) participants in study 1 and 8 (26.7 %)
participants in study 2; one participant discontinued
study 1 because of pruritus. Twelve of the 14 partici-
pants who vomited were women. The AE of vomiting
occurred in 6 participants under fasted conditions and
Fig. 2 Mean plasma concentration of APAP in (a) study 1 and (b) study 2. APAP = acetaminophen; ER = extended release; HB = hydrocodone
bitartrate; IR = immediate release
Table 4 AE incidence and most common TEAEs in all dosed participants in studies 1 and 2
AE, n (%) Study 1 (2 tablets IR/ER HB/APAP) Study 2 (3 tablets IR/ER HB/APAP)
High-fat meal Low-fat meal Fasted Overall High-fat meal Low-fat meal Fasted Overall
n = 43 n = 42 n = 45 n = 48 n = 24 n = 25 n = 28 n = 30
≥1 TEAE 15 (34.9) 11 (26.2) 15 (33.3) 26 (54.2) 6 (25.0) 6 (24.0) 9 (32.1) 15 (50.0)
≥1 SAE 0 0 0 0 0 0 0 0
≥1 severe TEAE 0 0 0 0 0 0 0 0
Treatment-related TEAEs 13 (30.2) 10 (23.8) 13 (28.9) 24 (50.0) 6 (25.0) 5 (20.0) 9 (32.1) 15 (50.0)
TEAEs leading to study discontinuation 2 (4.7) 2 (4.8) 3 (6.7) 7 (14.6) 3 (12.5) 1 (4.0) 4 (14.3) 8 (26.7)
Most common TEAEsa
Nausea 4 (9.3) 3 (7.1) 7 (15.6) 12 (25.0) 4 (16.7) 3 (12.0) 6 (21.4) 11 (36.7)
Vomiting 2 (4.7) 2 (4.8) 2 (4.4) 6 (12.5) 3 (12.5) 1 (4.0) 4 (14.3) 8 (26.7)
Dizziness 3 (7.0) 4 (9.5) 7 (15.6) 10 (20.8) 3 (12.5) 1 (4.0) 4 (14.3) 6 (20.0)
Headache 4 (9.3) 2 (4.8) 2 (4.4) 6 (12.5) 2 (8.3) 0 0 2 (6.7)
Feeling hot 0 0 1 (2.2) 1 (2.1) 0 1 (4.0) 2 (7.1) 3 (10.0)
Pruritus 1 (2.3) 0 1 (2.2) 2 (4.2) 2 (8.3) 0 1 (3.6) 3 (10.0)
AE = adverse event; APAP = acetaminophen; ER = extended release; HB = hydrocodone bitartrate; IR = immediate release; SAE = serious adverse event;
TEAE = treatment-emergent adverse event
aAffecting ≥10 % of participants in the overall group in either study
Devarakonda et al. BMC Pharmacology and Toxicology  (2015) 16:31 Page 8 of 10
in 3 and 5 participants after a low-and high-fat meal, re-
spectively. Five of 6 participants who vomited under
fasted conditions and all 3 who vomited after a low-fat
meal did so after receiving their first dose of study medi-
cation. In contrast, only 1 of 5 who vomited after a high-
fat meal did so after their first dose. In the remaining 5,
the dose taken was the second or third dose. The partici-
pant who discontinued after receiving the 2-tablet dose
because of moderate pruritus was treated with a single
25-mg dose of diphenhydramine, after which the AE
resolved.
The most commonly reported individual TEAEs
(affecting ≥10 % of participants in the overall group)
included nausea, vomiting, and dizziness in both studies.
In addition, headache after the 2-tablet dose and prur-
itus and feeling hot after the 3-tablet dose were reported
in ≥10 % of participants. After either dose, all TEAEs
were mild to moderate in severity. No severe or serious
TEAEs or deaths were reported.
No clinically meaningful changes in clinical laboratory
values, vital signs, or mean or individual oxygen satur-
ation values were reported. No 12-lead electrocardio-
gram abnormalities were noted, and no abnormal
physical examination result was considered a TEAE.
Discussion
Data from two phase 1 studies demonstrated that there
is only a minimal food effect with IR/ER HB/APAP 7.5/
325-mg tablets, not likely to be of clinical significance. A
high-fat meal did not have an effect on hydrocodone
total exposure or peak exposure after either a 2-tablet or
3-tablet dose. A low-fat meal did not affect total hydro-
codone exposure after a 2-tablet or 3-tablet dose but did
increase peak exposure after a 3-tablet dose by approxi-
mately 19 %. No effect of food on Cmax was noted after
the 2-tablet dose. These results are consistent with food
effects reported for other ER hydrocodone products,
where food, particularly a fatty meal, may produce mod-
est increases in hydrocodone Cmax but have no signifi-
cant effect on total absorption or require administration
on an empty stomach [11, 12]. After either IR/ER HB/
APAP dose, hydrocodone was rapidly absorbed under all
conditions, with no clinically relevant lag in the appear-
ance of plasma concentrations when administered with
food. There was a single peak with no trough between
the IR and ER phases, suggesting that the objective of
rapid onset of effect with sustained activity thereafter
has been achieved.
A high-fat meal decreased APAP Cmax by appro-
ximately 20 % after a 2-tablet dose and 13 % after a
3-tablet dose compared with fasted conditions. A low-fat
meal did not have an effect on total APAP exposure with
either dose. However, a low-fat meal decreased peak ex-
posure of APAP by approximately 20 % after the 2-tablet
dose and 21 % after the 3-tablet dose compared with
fasted conditions. Because food had no effects on total ex-
posure, these modest decreases in peak exposure are not
expected to be clinically significant or necessitate dosage
adjustments. After either dose, APAP was rapidly ab-
sorbed under all conditions, with no clinically relevant lag
in the appearance of plasma concentrations when admin-
istered with food.
Differences in pharmacokinetic results after a 2-tablet
dose (study 1) compared with the 3-tablet dose (study 2)
were apparent, although inferences about the relative
properties of the 2 doses are based on numerical dif-
ferences without formal statistical analysis. For hydroco-
done, mean AUC0–t, AUC0–inf, and Cmax were larger in
participants who received 3 tablets regardless of fed state
compared with participants who received 2 tablets.
Under all conditions, mean t½ was slightly longer in par-
ticipants who received 2 tablets compared with those who
received 3 tablets. For APAP, mean AUC0–t, AUC0–inf, and
Cmax were larger in participants who received 3 tablets re-
gardless of fed state compared with participants who re-
ceived 2 tablets. When comparing each fed state (high-fat,
low-fat, and fasting), mean t½ was slightly longer in partic-
ipants who received 3 tablets compared with those who
received 2 tablets. Thus, hydrocodone and APAP exposure
increased in a predictable manner when the dose in-
creased under all conditions, regardless of food intake.
In the present analysis, following a single dose of IR/
ER HB/APAP 7.5/325 mg 2 tablets, nausea was reported
in 25 % of participants and vomiting in 13 %; following a
single dose of IR/ER HB/APAP 7.5/325 mg 3 tablets,
nausea was reported in 37 % of participants and vomit-
ing in 27 %. No severe or serious TEAEs were reported
under any treatment condition, and there were no clinic-
ally meaningful abnormalities of laboratory values,
changes in vital signs, oxygen saturation, electrocardio-
gram results, or physical examination findings. No not-
able safety differences were observed between the fed
(high-fat and low-fat meals) and fasted treatment groups
in either study, with the exception of the TEAEs of nau-
sea and vomiting. Almost all participants who vomited
were women, which is consistent with research showing
that women are more susceptible to vomiting during
opioid therapy [13]. Reasons for this disparity be-
tween men and women are not clear. However, there
are data suggesting that hormonal factors, differences
in sensitivity to opioid agonism, and other factors
may be involved [14].
The safety profile of single, 2-tablet and 3-tablet doses
of IR/ER HB/APAP was consistent with expectations for
a low-dose combination opioid analgesic. In a random-
ized, double-blind, placebo- and active-controlled study,
63 patients who had undergone impacted molar extrac-
tion received a single dose of IR HB/APAP 7.5/500 mg,
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with ibuprofen (dosage not specified) available as rescue
medication; during 6 h of follow-up, nausea and vomiting
were reported in 16 and 8 % of patients, respectively [15].
Short-term multi-dose studies of IR HB/APAP at doses of
5/325 mg and 7.5/650 mg and IR HB/ibuprofen 7.5/
200 mg 1–2 tablets have reported nausea in 21 to 36 %
and vomiting in 4 to 13 % of patients, respectively [16–18].
A limitation of this analysis is that elderly, pediatric, and
substantially over- or underweight patients were not rep-
resented. Patients with significant illnesses that might
affect pharmacokinetics or tolerability were also excluded,
and demographic diversity was limited, with only 1
participant each of Asian and American Indian/Alaskan
Native descent participating in study 2.
Conclusions
Food intake had no effect on overall exposure to hydro-
codone or APAP with IR/ER HB/APAP. Small changes
in Cmax for both hydrocodone and APAP were observed
under fed versus fasted conditions; however, these differ-
ences were not considered clinically meaningful. IR/ER
HB/APAP was generally well tolerated, with a TEAE
profile typical of low-dose opioid combination analge-
sics, and there was no indication that food intake had
any effect on safety. These results suggest that IR/ER
HB/APAP can be administered without regard to food.
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